RE:RE: Novartis and Legend Biotech Sign Exclusive License Agreemen" At this point, there’s no sign that either GenScript or Legend will be added to the BIOSECURE Act’s list of target companies, which could be barred from contracting with the U.S. government and effectively pushed out of the U.S. market. But it’d be logical if J&J wanted to mitigate the risk by removing the Chinese tie and taking Legend’s operations into its own hands."
"Novartis has said its M&A focus is currently on deals worth around [or below] $5 billion. But the company did in 2020 acquire The Medicines Company for $9.7 billion. "
https://www.fiercepharma.com/pharma/jjs-car-t-partner-legend-biotech-reportedly-receives-buyout-offer